THU0129 The Effectiveness of Biologic Agents Concomitant with Tacrolimus in Rheumatoid Arthritis
Authors: K. Terabe, N. Takahashi, K. Funahashi, A. Kaneko, Y. Yabe, Y. Hirano, T. Kojima, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In Japan, oral tacrolimus (TAC) was approved for the treatment of RA in 2005 and the improvement of symptoms thorough the use concomitant with disease modifying antirheumatic drugs (DMARDs), including MTX has been reported<sup>1,2</sup>. On the other hand, the efficacy and tolerance of biological agents therapy concomitant with TAC are unknown. <h3>Objectives</h3> The objective of this study was to investigate the efficacy and tolerance of biological agents concomitant with TAC in Japanese patients with RA using retention rate analysis. <h3>Methods</h3> Total patients (n=1541) who underwent 4 biological agents (etanercept: ETN, adalimumab: ADA, tocilizumab: TCZ, abatacept: ABT) treatment between 2003 and 2011 at Nagoya University Hospital and 12 other institutes (Tsurumai Biologics Communication Study Group) were enrolled<sup>3</sup>. In each biologics analysis, patients were divided into three groups: (1) concomitant only MTX (MTX group) (2) concomitant only TAC (TAC group) (3) monotherary (mono group). In TAC or MTX group, these drugs were only ones which concomitant with biologics. Patients who underwent biologics combined with other DMARDs were excluded. Kaplan-Meier analysis was used to estimate retention rate in each biologics group. To estimate the tolerance of concomitant biologics with TAC, cumulative hazard function was performed in each biologics group. <h3>Results</h3> In total 1541 patients, 91 patients (5.9%) administered each biologics concomitant with TAC (ETN: n=38, 101.0 patient-years (PY) ADA: n=13, 12.8 PY TCZ: n=24, 40.8 PY ABT: n=17, 16.2 PY). Average dosages of TAC at starting were ETN: 2.1±0.7mg ADA: 1.5±1.0mg TCZ: 2.2±0.9mg ABT: 2.4±0.9mg. With comparison of retention rate in each biologics concomitant with TAC, ADA was significantly lower rate than other 3 biologics (Fig. 1). Each biologics agent9s number was ETN (MTX: n=641, 1473.0 PY mono: n=194, 469.1PY), ADA (MTX: n=641, 1473.0 PY mono: n=34, 35.2PY), TCZ (MTX: n=181, 247.5 PY mono: n=85, 120.0PY), ABT (MTX: n=85, 89.6 PY mono: n=38, 35.1PY). In only ETN analysis, the retention rate of TAC group was higher than mono group (Fig. 2). In ADA, that of MTX group was higher than TAC and mono group. There was no difference of comparison that of other 2 biologics analysis. Comparison of incidence of adverse event between TAC and mono group using cumulative hazard function in each biologics analysis, in only ETN analysis incident rate of mono group was higher than TAC group and there was no difference in other 3 biologics analysis (Fig. 3). <h3>Conclusions</h3> We suspected that combination therapy ETN and TAC are subsequent options for treatment to RA patient, especially in whom MTX cannot be administration. <h3>References</h3> Kino T, et al. Antibiot. 1987 Sep 40(9): 1256-65 Kondo H, et al. J Rheumatol. 2004 Feb;31(2):243-51 Kojima T, et al. Mod Rheumatol. 2011 Sep 3. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3634